Vantage logo

Ash 2020 roundup

Evaluate Vantage's coverage of the virtual Ash 2020 congress.

Vantage logo

Is valrox dead?

Valrox leaves a disproportionate hole in Biomarin’s valuation, but gene therapy competitors shouldn’t celebrate just yet.

Vantage logo

No buyout for Uniqure

But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.